Literature DB >> 9039461

Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease?

T G Beach1, W G Honer, L H Hughes.   

Abstract

Diffuse plaques are the earliest Alzheimer-type lesions in Down's syndrome and are a putative marker for the preclinical stage of Alzheimer's disease (AD). As a cerebral cortical cholinergic deficit is one of the characteristics which defines AD, we examined the brains of individuals who had died without a history of neurological disease to determine whether this deficit is present in association with diffuse plaques. Of the 24 cases collected, 14 were older than 60 years of age (mean 69.2 years) and 10 were younger (mean 29.6 years). Of the 14 older cases, 9 had diffuse plaques in the entorhinal cortex (ECx) and/or inferior temporal gyrus (ITG). The older cases were divided into two groups (plaque-positive or plaque-negative cases). These groups did not differ significantly with respect to age, post-mortem delay, synaptophysin immunoreactivity or neurofibrillary tangle density. Cholinergic fibre densities were estimated in sections stained using acetylcholinesterase (AChE) enzyme histochemistry. Mean AChE fibre density was decreased in both the ITG and ECx (approximately 30% and 50% depletion, respectively) in the plaque-positive group compared to the plaque-negative group and in both areas the mean fibre density of the plaque-positive group was about 50% of that in the younger group. These results suggest that diffuse plaques in the non-demented elderly are associated with an accelerated age-related cortical cholinergic deficit and, therefore represent the preclinical stage of AD.

Entities:  

Mesh:

Year:  1997        PMID: 9039461     DOI: 10.1007/s004010050595

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  17 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

2.  Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission.

Authors:  Saak V Ovsepian; Valerie B O'Leary; Laszlo Zaborszky
Journal:  Neuroscientist       Date:  2015-05-22       Impact factor: 7.519

3.  C-terminal fragments of amyloid-beta peptide cause cholinergic axonal degeneration by a toxic effect rather than by physical injury in the nondemented human brain.

Authors:  Peter Kasa; Henrietta Papp; Janos Zombori; Peter Mayer; Frederic Checler
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

4.  Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects.

Authors:  Michel J Grothe; Michael Ewers; Bernd Krause; Helmut Heinsen; Stefan J Teipel
Journal:  Alzheimers Dement       Date:  2014-01-10       Impact factor: 21.566

5.  Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging.

Authors:  Thomas G Beach; Lucia I Sue; Douglas G Walker; Marwan N Sabbagh; Geidy Serrano; Brittany N Dugger; Monica Mariner; Kim Yantos; Jonette Henry-Watson; Glenn Chiarolanza; Jose A Hidalgo; Leslie Souders
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

6.  Lentiviral infection of rhesus macaques causes long-term injury to cortical and hippocampal projections of prostaglandin-expressing cholinergic basal forebrain neurons.

Authors:  Candan Depboylu; Eberhard Weihe; Lee E Eiden
Journal:  J Neuropathol Exp Neurol       Date:  2012-01       Impact factor: 3.685

7.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease.

Authors:  Pamela E Potter; Paula K Rauschkolb; Yoga Pandya; Lucia I Sue; Marwan N Sabbagh; Douglas G Walker; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2011-05-01       Impact factor: 17.088

8.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.

Authors:  G W Small; L M Ercoli; D H Silverman; S C Huang; S Komo; S Y Bookheimer; H Lavretsky; K Miller; P Siddarth; N L Rasgon; J C Mazziotta; S Saxena; H M Wu; M S Mega; J L Cummings; A M Saunders; M A Pericak-Vance; A D Roses; J R Barrio; M E Phelps
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 9.  The application of positron-emitting molecular imaging tracers in Alzheimer's disease.

Authors:  Robert M Cohen
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

10.  Selective lesion of medial septal cholinergic neurons followed by a mini-stroke impairs spatial learning in rats.

Authors:  Laura A Craig; Nancy S Hong; Joelle Kopp; Robert J McDonald
Journal:  Exp Brain Res       Date:  2008-10-21       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.